CSCs are notoriously resistant to conventional treatments like chemotherapy and radiation, often surviving initial treatment and leading to subsequent tumor relapse. Developing therapies that specifically target the mechanisms driving CSCs, such as their unique metabolism or survival signaling pathways, is a priority. Inhibitors of pathways like Wnt, Notch, or Hedgehog, which are ofte... https://www.beatcancerfoundation.org/